Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $40.6 million.

  • Ultragenyx Pharmaceutical's Accounts Payables rose 1273.41% to $40.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.6 million, marking a year-over-year increase of 1273.41%. This contributed to the annual value of $38.8 million for FY2024, which is 797.36% down from last year.
  • As of Q3 2025, Ultragenyx Pharmaceutical's Accounts Payables stood at $40.6 million, which was up 1273.41% from $34.2 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Accounts Payables high stood at $59.8 million for Q2 2024, and its period low was $15.6 million during Q3 2021.
  • In the last 5 years, Ultragenyx Pharmaceutical's Accounts Payables had a median value of $36.0 million in 2024 and averaged $35.2 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first surged by 15250.32% in 2022, then plummeted by 4274.58% in 2025.
  • Ultragenyx Pharmaceutical's Accounts Payables (Quarter) stood at $17.1 million in 2021, then skyrocketed by 152.5% to $43.3 million in 2022, then decreased by 2.68% to $42.1 million in 2023, then dropped by 7.97% to $38.8 million in 2024, then rose by 4.69% to $40.6 million in 2025.
  • Its last three reported values are $40.6 million in Q3 2025, $34.2 million for Q2 2025, and $47.4 million during Q1 2025.